期刊文献+

来氟米特联合糖皮质激素治疗进展性IgA肾病的疗效及对VCAM-1水平的影响 被引量:36

Effect of Leflunomide Combined with Glucocorticoid in the Treatment of Progressive IgA Nephropathy and Its Influence on VCAM-1 Level
原文传递
导出
摘要 目的:研究来氟米特联合糖皮质激素治疗进展性IgA肾病的疗效及对尿VCAM-1水平的影响。方法:选择2012年5月至2014年5月在我院接受治疗的进展性IgA肾病患者104例作为研究对象。按照随机数字表法分成实验组及对照组各52例,对照组予以常规治疗方案联合泼尼松药物治疗,实验组基于对照组基础另予来氟米特治疗,疗程均为6个月。采用全自动生化分析仪测定并比较两组患者治疗前后24 h尿蛋白定量、血白蛋白、血肌酐、肾小球滤过率(GFR)及尿血管细胞黏附分子(尿VCAM-1)水平,评价治疗后两组患者的临床疗效和药物不良反应。结果:(1)实验组的总有效率为94.23%,显著高于对照组的80.77%(P<0.05);(2)两组治疗后尿蛋白定量、血肌酐水平及尿VCAM-1水平均显著低于治疗前,且实验组低于对照组;而治疗后血白蛋白及GFR水平均分别显著高于治疗前,实验组高于对照组(均P<0.05);(3)治疗后实验组的药物总不良反应发生率与对照组相比,差异无统计学意义(P>0.05)。结论:利用来氟米特与糖皮质激素联合治疗进展性IgA肾病患者,具有较好的疗效,可降低尿VCAM-1水平,且不会增加不良反应的发生,值得在临床推广应用。 Objective: To study the effect of leflunomide combined with glucocorticoid in the treatment of progressive IgA nephropathy and its influence on urine vascular cell adhesion molecule(VCAM-1) level.Methods: Selected 104 patients with progressive IgA nephropathy who were treated in our hospital from May 2012 to May 2014 as the research objects.They were divided into experimental group and control group with 52 patients in each group according to the random number table method,the control group was received conventional treatment combined with prednisone therapy,while the experimental group was added leflunomide based on the therapy of control group,the course of treatment were 6 months.Detected and compared the levels of urine protein,serum albumin,serum creatinine,glomerular filtration rate(GFR) and urine VCAM-1 in the two groups 24 h before and after treatment by automatic biochemical analyzer,and evaluated the clinical efficacy and drug adverse reactions in two groups after treatment.Results:(1)The total effective rate in the experimental group was 94.23%,which was significantly higher than 80.77% in the control group(P〈0.05);(2)The urine protein,serum creatinine and urine VCAM-1 levels in the two groups after treatment were significantly lower than before treatment,and the experimental group was lower than control group; While the serum albumin and GFR were significantly higher than before treatment,and the experimental group was higher than control group(P〈0.05);(3)There was no significant difference in the total drug adverse reactions between the experimental group and the control group(P〈0.05).Conclusion: Leflunomide combined with glucocorticoid has good clinical efficacy in the treatment of patients with progressive IgA nephropathy,which can reduce the urine VCAM-1 level,and will not increase the incidence of drug adverse reactions,it is worth popularizing and applying in clinical field.
出处 《现代生物医学进展》 CAS 2016年第11期2134-2137,共4页 Progress in Modern Biomedicine
关键词 来氟米特 糖皮质激素 进展性IgA肾病 疗效 VCAM-1 Leflunomide Glucocorticoid Progressive IgA nephropathy Effect VCAM-1
  • 相关文献

参考文献2

二级参考文献37

  • 1Donadio JV, Grande JP. IgA nephropathy [J]. N Engl J Med,2002,347 (10):738-748.
  • 2Petera P, Manger B, Manger K, et al. A pilot study of leflunomide in systemic Lupus erythematosus[J].Arthrit Rheum,2000,43(suppl): 241-245.
  • 3Locatelli F, Pozzi C, Del Vecchio L, et al. Role of proteinuria re- duction in the progression oflgA nephropathy [J]. Ren Fail,2001, 23(3):495-505.
  • 4Bllardie FW, Roberts I S. Controlled prospective trial of predniso- lone and cytotoxics in progressive IgA nephropathy [J]. J Am Soc Nephrol,2002,13(1): 142-148.
  • 5Szeto CC, Lai FM-M, To KF, et al .The natural history ofimmun- oglobin A nephropathy among patients with hematuria andminiral proteinuria[J].AmJ Med,2001,110(3):434-437.
  • 6Finnegan A, Siemasko KF, Williams JW, et al. Leflunomide inhib- its immunoglobin production by two separate mechanism [J].ACR Poster Session, 1997,10( 1 ):40.
  • 7Dimitrora P, Skapenko A, Schleyerbach R.Immunomodulatory functions of leflunomide: inhibition fo Th 1 cell activation and pro- motion of Th2 differentiation[J]. Arthritis Rlaeum,2001,44(suppl): S216.
  • 8Raij L,Azar S,Keane W. Mesangial immune injury,hypertension,and progressive glomerular damage in Dahl rats[J].Kidney International,1984,(02):137-143.
  • 9Nikibakhsh AA,Mahmoodzadeh H,Karamyyar M. Treatment of steroid and cyclosporine-resistant idiopathic nephrotic syndrome in children[J].I Int J Nephrol,2011.930965.
  • 10D'Agati VD. Pathobiology of focal segmental glomerulosclerosis:new developments[J].Current Opinion in Nephrology and Hypertension,2012,(03):243-250.

共引文献7

同被引文献262

引证文献36

二级引证文献120

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部